UCN-01 and Fludarabine in Treating Patients With Recurrent or Refractory Lymphoma or Leukemia

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

RATIONALE: Drugs used in chemotherapy work in different ways to stop cancer cells from dividing so they stop growing or die. Combining UCN-01 with chemotherapy may kill more tumor cells.

PURPOSE: This phase I trial is studying the side effects and best dose of fludarabine when given with UCN-01 in treating patients with recurrent or refractory low-grade lymphoma or leukemia.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: National Cancer Institute (NCI)
• Treatments: 7-hydroxystaurosporine; Fludarabine; Fludarabine phosphate; Staurosporine; Vidarabine

Criteria

DISEASE CHARACTERISTICS:

• Histologically confirmed recurrent or refractory low-grade or indolent lymphoid malignancies requiring systemic therapy, including the following:

• Grade I or II follicular small cleaved cell lymphoma

• Small lymphocytic lymphoma/leukemia subtypes (chronic lymphocytic leukemia)

• Mantle cell lymphoma

• Waldenstrom's macroglobulinemia

• Lymphoplasmacytoid

• Marginal zone (nodal, extranodal, or splenic subtypes)

• Hairy cell leukemia

• Transformed indolent subtypes allowed provided 1 of the following criteria are met:

• Previously treated with a doxorubicin-containing regimen

• No rapidly progressing disease that threatens vital functions

• Measurable disease

• No active leptomeningeal or parenchymal CNS lymphoma NOTE: A new classification scheme for adult non-Hodgkin's lymphoma has been adopted by PDQ. The terminology of "indolent" or "aggressive" lymphoma will replace the former terminology of "low", "intermediate", or "high" grade lymphoma. However, this protocol uses the former terminology.

PATIENT CHARACTERISTICS:

Age:

• 18 and over

Performance status:

• Karnofsky 60-100%

Life expectancy:

• Not specified

Hematopoietic:

• Absolute neutrophil count at least 1,000/mm^3

• Platelet count at least 50,000/mm^3

• No active Coomb's-positive hemolytic anemia

Hepatic:

• Total bilirubin less than 2.0 mg/dL (unless elevation is due to Gilbert's disease and direct bilirubin is normal)

Renal:

• Creatinine less than 1.5 mg/dL OR

• Creatinine clearance greater than 60 mL/min

Cardiovascular:

• No angina

• No congestive heart failure

• No myocardial infarction within the past 6 months

Other:

• Not pregnant or nursing

• Negative pregnancy test

• Fertile patients must use effective contraception

• HIV negative

• No insulin-dependent diabetes mellitus

PRIOR CONCURRENT THERAPY:

Biologic therapy:

• Not specified

Chemotherapy:

• See Disease Characteristics

• More than 3 weeks since prior systemic chemotherapy and recovered

Endocrine therapy:

• More than 3 weeks since prior systemic steroid therapy and recovered

Radiotherapy:

• Not specified

Surgery:

• Not specified